Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This prospective, randomized controlled study is intended to enroll 152 patients in the early
stages of donor kidney transplantation at six clinical centers in China between January 2023
and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to
either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of follow-up
(before enrollment) and each follow-up point, all clinical indicators of patients were
recorded to measure the therapeutic effect.